多耐药基因在乳腺癌组织中表达及临床意义  

Expression of mdr1,MRP,LRP,GST-π,TOPOⅡα and BCRPgene in breast cancer and its clinical significance

作　　者：曾爱华[1] 何蕴韶[2] 

机构地区：[1]广东药学院药科学院,广东广州510006 [2]中山大学达安基因诊断中心,广东广州510008

出　　处：《中国热带医学》2013年第4期496-497,500,共3页China Tropical Medicine

摘　　要：目的全面了解乳腺癌内源性耐药情况,实现肿瘤病人个体化化疗。方法应用荧光定量PCR方法检测51例术前未经化疗的乳腺癌和癌旁组织中mdr1、MRP、LRP、GST-π、TOPOⅡα、BCRP基因表达。结果这6个多药耐药基因在乳腺癌组织和癌旁组织中的阳性表达率均有显著统计学意义;mdr1、LRP、GST-π、TOPOⅡα在乳腺癌组织和癌旁组织之间的表达水平无显著统计学意义(P>0.05);MRP和BCRP在乳腺癌组织中的表达水平显著高于其在癌旁组织中的表达水平,差异有统计学意义(P<0.05)。结论 MRP和BCRP可能与乳腺癌的内源性耐药有关,mdr1、LRP、GST-π、TOPOⅡα的表达可能与乳腺癌的内源性耐药无关,乳腺癌患者进行术前的新辅助化疗是可行的。Objective To understand the intrinsic MDR and realize individualized chemotherapy of breast cancer patients and improve therapeutic effect.Methods The expression levels of mdr1,MRP,LRP,GST-π,TopoIIα,BCRP genes in 51 breast cancer patients and paracarcinoma tissue without adjuvant chemotherapy were determined by the FQ-PCR.Results The positive rates of mdr1,MRP,LRP,GST-π,TopoIIα,BCRP expression were significantly different between breast cancer and paracarcinoma tissues.The expression levels of mdr1,LRP,GST-π,TopoIIα were not significantly different between breast cancer and paracarcinoma tissues,but expression levels of MRP and BCRP in breast cancer patients were significantly higher than that of the paracarcinoma tissues（P0.05）.Conclusions The expression levels of MRP,BCRP were associated with intrinsic MDR,the expression levels of mdr1,LRP,GST-π,TopoIIα were not related to intrinsic MDR of breast cancer,The adjuvant chemotherapy is feasible in treatment of breast cancer.

关 键 词：乳腺癌 多药耐药 基因 表达 

分 类 号：R737.9[医药卫生—肿瘤]